| Project/Area Number |
22791529
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
ISOBE Aki 大阪大学, 大学院・医学研究科, 助教 (60397619)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 卵巣癌 / 腹膜播種 / TAM / IL-6 / tocilizumab |
|---|
| Research Abstract |
Ascites were collected aseptically, and CD11b positive cells(TAMs) were purified by positive selection using magnetic-activate cell sorting(MACS) technology. Co-culture of ovarian cancer cell line, SKOV3ip1 cells, with TAMs significantly enhanced the invasive activity of cancer cells in Matrigel Boyden chamber assay. This enhancement was partially blolcked by the treatment of anti-interleukin(IL)-6 receptor antibody(Tocilizumab). Since SKOV3ip1 cells did not express IL-6 in mRNA and protein level, IL-6 secreted by TAMs were considered to play a key role in ovarian cancer invasion. In vivo ovarian cancer xenografts, i. p. treatment of Tocilizumab significantly reduced peritoneal dissemination and ascites formation. Those results suggested targeting IL-6 produced by TAMs could be a promising therapy for a subset of ovarian cancer patients.
|
